Noonan syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Noonan syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone https://clinicaltrials.eu/trial/study-of-vosoritide-for-children-with-turner-syndrome-short-stature-homeobox-containing-gene-deficiency-and-noonan-syndrome-not-responding-to-growth-hormone/ Wed, 29 Apr 2026 15:03:11 +0000 https://clinicaltrials.eu/trial/study-of-vosoritide-for-children-with-turner-syndrome-short-stature-homeobox-containing-gene-deficiency-and-noonan-syndrome-not-responding-to-growth-hormone/ This clinical trial is focused on studying the effects of a treatment called vosoritide in children with certain growth-related conditions. These conditions include Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome. These are genetic conditions that can affect growth and development in children. The study will compare the effects of vosoritide with those of continued treatment with human growth hormone (hGH), which is a common treatment for these conditions.

The purpose of the study is to evaluate how different doses of vosoritide affect growth in children who have not responded adequately to hGH. The study will involve children who have been receiving hGH for at least a year. Participants will be randomly assigned to receive either vosoritide or continue with hGH. The study will last for several months, during which the growth of the children will be monitored and compared.

Throughout the study, researchers will observe changes in growth and monitor for any side effects. The study aims to provide insights into whether vosoritide can be an effective alternative or addition to hGH for improving growth in children with these specific conditions. The study will also track other health indicators to ensure the safety and effectiveness of the treatment. The results will help determine if vosoritide can be a beneficial treatment option for children with these growth challenges.

]]> Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature https://clinicaltrials.eu/trial/study-comparing-somapacitan-and-somatropin-for-growth-in-children-with-short-stature-due-to-small-for-gestational-age-turner-syndrome-noonan-syndrome-or-idiopathic-short-stature/ Wed, 29 Apr 2026 14:27:17 +0000 https://clinicaltrials.eu/trial/study-comparing-somapacitan-and-somatropin-for-growth-in-children-with-short-stature-due-to-small-for-gestational-age-turner-syndrome-noonan-syndrome-or-idiopathic-short-stature/ This clinical trial is focused on children with short stature, which means they are shorter than most children their age. The study includes children who were either born small for their age, or have conditions like Turner syndrome, Noonan syndrome, or idiopathic short stature, which means the cause of their short stature is unknown. The trial is testing a new treatment called somapacitan, which is given once a week, and comparing it to a daily treatment called Norditropin®. Both treatments are designed to help children grow taller.

The purpose of the study is to see if the once-weekly somapacitan is as effective as the daily Norditropin® in helping children grow. The study will last for a period of time, during which children will receive either somapacitan or Norditropin®. The somapacitan is administered using a special pen-injector called the PDS290 pen-injector, which is a pre-filled device that makes it easier to give the injection. The study will monitor the children’s growth over time, specifically looking at how fast they grow in height.

Throughout the study, researchers will also keep an eye on the long-term safety of somapacitan. They will measure various health indicators, such as changes in bone age and levels of certain substances in the blood, like IGF-I and IGFBP-3, which are related to growth. The study aims to provide valuable information on whether somapacitan can be a safe and effective option for children with short stature conditions.

]]> Study on the Safety and Effectiveness of Somapacitan for Children with Short Stature Due to Noonan Syndrome, Turner Syndrome, Small for Gestational Age, or Idiopathic Short Stature https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-somapacitan-for-children-with-short-stature-due-to-noonan-syndrome-turner-syndrome-small-for-gestational-age-or-idiopathic-short-stature/ Wed, 29 Apr 2026 14:24:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-somapacitan-for-children-with-short-stature-due-to-noonan-syndrome-turner-syndrome-small-for-gestational-age-or-idiopathic-short-stature/ This clinical trial is focused on studying the safety and effectiveness of a medication called Somapacitan in children who have difficulty growing. The study includes children with conditions such as Turner syndrome, Noonan syndrome, being born small for gestational age, or having idiopathic short stature, which means short stature without a known cause. Somapacitan is given as a solution for injection under the skin, using a special pen-injector designed for single patient use.

The purpose of the study is to evaluate how safe Somapacitan is and how well it works in helping children grow. Participants in the study will receive the medication once a week. The study will monitor the number of any adverse events, which are unexpected medical problems, over a period of time. The study will also look at how the children’s height changes during the study.

The study will take place over several weeks, with regular check-ups to monitor the children’s growth and any side effects they might experience. The goal is to gather information on how Somapacitan affects growth in children with these specific conditions, providing valuable insights into its potential benefits and safety.

]]>